The U.S. Food and Drug Administration (FDA) announced a significant revision to the label for tofacitinib (Xeljanz, Xeljanz XR), effective 2026-06-02. This update includes the addition of a new boxed warning, the agency's strongest safety alert, to highlight several serious risks associated with the medication. These risks specifically include serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis.
Background
Tofacitinib, known by its brand names Xeljanz and Xeljanz XR, is a medication that has undergone a significant label revision by the U.S. Food and Drug Administration. The active pharmaceutical ingredient is tofacitinib citrate. This update specifically concerns the safety information provided to healthcare providers and patients regarding the use of the drug.
What this means
The addition of a boxed warning to the tofacitinib label represents a critical communication from the FDA regarding the drug's safety profile. This type of warning, the most serious issued by the agency, is intended to draw attention to significant risks that may lead to severe outcomes, including death. For patients treated with tofacitinib, the label now explicitly states an increased risk for serious infections. These can include various types of infections such as bacterial, fungal, and viral infections, which may require hospitalization or prove fatal. Beyond infections, the warning also addresses an elevated risk of mortality, meaning a higher chance of death, and an increased incidence of malignancy, or cancer. Furthermore, the label now cautions about a heightened risk of major adverse cardiovascular events (MACE), which encompass serious heart-related issues, and thrombosis, referring to the formation of blood clots. Clinicians prescribing tofacitinib must carefully weigh these substantial risks against the potential benefits for each individual patient. This includes thorough patient screening, ongoing monitoring for signs and symptoms of these adverse events, and comprehensive patient education regarding the potential dangers of the therapy. The update reinforces the need for vigilant risk management strategies in clinical practice, emphasizing the importance of patient counseling on these serious risks before and during treatment.
Source
The information regarding this label revision for tofacitinib was sourced from the FDA, as detailed in a DailyMed document. The update, effective 2026-06-02, is accessible via dailymed.nlm.nih.gov.